The study was a double blind placebo controlled study adequately powered for OS as primary end-point.
这项研究是一项双盲,安慰剂对照的研究,以OS作为主要终止点。
So, in fact, this double blind placebo controlled study does not guarantee safety or efficacy because the test leaves far too many questions unanswered.
所以实际上,双盲对照研究并不会保证疗效和安全,因为它留下太多无法回答的问题。
The answer is the "gold standard" double blind, placebo controlled study.
答案是“金标准”,双盲,安慰剂对照研究。
应用推荐